English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Results 123 (61%) were on S, 103 had complete data available 84 patients (81%) resumed or continued selegiline. Of these. 43 (42%) remained on, or resumed 10 mg. dose. 39(37%) resumed 5mg, and 1 (1%) each 2.5 or 1.25 mg. Only 19 (18%) patients stopped S and remained off it Of these, no change in PD medications 7; Increased dopa 6 (ave. +200mg (+32%), Decreased dopa 1 ; Increased agonist 2 (400% increase), Added agonist 1 ; Changed agonist 1

An Audit of a Protocol Showing the Effects of Withdrawal of Selegiline from Patients with Parkinson's Disease